Glioma angiogenesis is boosted by ELK3 activating the HIF-1α/VEGF-A signaling axis

Clinical studies have shown that first-line use of anti-angiogenetic therapy can prolong progressionfree survival but little progress has been made in extending the overall survival of the patients. We explored the role of ELK3 in glioma angiogenesis to improve and design more efficacious therapies.